Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1978)
•••
Post by lscfaon Jul 25, 2022 3:40pm
149 Views
Post# 34849141

Carbohydrate-based drugs launched during 2000−2021

Carbohydrate-based drugs launched during 2000−2021

Table 1. The carbohydrate-based drugs launched during 2000–2021.

No. Generic name Indications Year Country Chemical category
1 Remedesivir Antiviral 2020 USA Nucleoside
2 Molnupiravir Antiviral 2021 UK Nucleoside
3 Azvudine Antiviral 2021 China Nucleoside
4 Entecavir Antiviral 2005 USA Nucleoside
5 Telbivudine Antiviral 2006 USA Nucleoside
6 Clevudine Antiviral 2006 South Korea Nucleoside
7 Sofosbuvir Antiviral 2013 USA Nucleoside
8 Maribavir Antiviral 2021 USA Nucleoside
9 Peramivir Antiviral 2010 Japan Nucleoside
10 Laninamivir Octanoate Antiviral 2010 Japan Nucleoside
11 Carragelose Antiviral 2013 Europe NP-deriveda
12 Telithromycin Antibacterial 2001 USA NP-derived
13 Cethromycin Antibacterial 2009 USA NP-derived
14 Carrimycin Antibacterial 2019 China NP-derived
15 Fidaxomicin Antibacterial 2011 USA NP-derived
16 Telavancin Antibacterial 2009 USA NP-derived
17 Oritavancin Antibacterial 2014 USA NP-derived
18 Dalbavancin Antibacterial 2014 USA NP-derived
19 Plazomicin Antibacterial 2018 USA NP-derived
20 Paromomycin Antiparasitic 2006 India NP-derived
21 Azacitidine Anticancer 2004 USA Nucleoside
22 Decitabine Anticancer 2006 USA Nucleoside
23 Clofarabine Anticancer 2004 USA Nucleoside
24 Nelarabine Anticancer 2005 USA Nucleoside
25 Forodesine Anticancer 2017 Japan Nucleoside
26 Amrubicin Anticancer 2002 Japan NP-derived
27 Midostaurin Anticancer 2017 USA NP-derived
28 Mifamurtide Anticancer 2009 Europe NP-derived
29 Dapagliflozin Antidiabetic 2012 Europe NP-derived
30 Canagliflozin Antidiabetic 2013 USA NP-derived
31 Empagliflozin Antidiabetic 2014 Europe NP-derived
32 Ipragliflozin Antidiabetic 2014 Japan NP-derived
33 Luseogliflozin Antidiabetic 2014 Japan NP-derived
34 Tofogliflozin Antidiabetic 2014 Japan NP-derived
35 Ertugliflozin Antidiabetic 2017 USA NP-derived
36 Sotaglifozin Antidiabetic 2019 Europe NP-derived
37 Remogliflozin Etabonate Antidiabetic 2019 India NP-derived
38 Tinzaparin sodium Cardiovascular/anticoagulant 2000 USA NP-derived
39 Fondaparinux Sodium Cardiovascular/anticoagulant 2001 USA NP-derived
40 Ticagrelor Cardiovascular 2010 Europe Nucleoside
41 Cangrelor Cardiovascular 2015 USA Nucleoside
42 Sodium oligomannate Alzheimer Disease 2019 China NP-derived
43 Sugammadex Anesthesia 2008 Europe NP-derived
44 Diquafosol tetrasodium Dry eye disease 2010 Japan Nucleoside
45 Lactitol Chronic idiopathic constipation 2020 USA NP-derived
46 Magnesium isoglycyrrhizinate Anti-inflammatory 2005 China NP-derived
47 Miglustat Gaucher disease 2002 Europe NP-derived
48 Migalastat Fabry disease 2016 Europe NP-derived
49 Uridine Triacetate Hereditary orotic aciduria 2015 USA Nucleoside
50 Regadenoson Myocardial perfusion imaging 2008 USA Nucleoside
51 [99mTc]Tilmanocept Contrast media 2013 USA NP-derived
52 Givosiran siRNA for AHP 2019 USA Glycoconjugate
53 S. Pneumoniae vaccines S. Pneumoniae prevention 2000–2021 USA, Europe, etc. Glycoconjugate
54 Typhim Vi vaccine Typhim prevention 2014 USA Glycoconjugate
a

NP-derived: derived from natural product.


https://www.sciencedirect.com/science/article/pii/S2211383522002428
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities